Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Comprehensive analysis of the complexity and heterogeneity of the lncRNAs transcriptome in multiple myeloma

ABSTRACT: Comprehensive analysis of the complexity and heterogeneity of the lncRNAs transcriptome in multiple myeloma

PROVIDER: PRJNA553573 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR9662121_1.fastq.gz	Fastqsanger.gz
	SRR9662121_2.fastq.gz	Fastqsanger.gz
	SRR9662122_1.fastq.gz	Fastqsanger.gz
	SRR9662122_2.fastq.gz	Fastqsanger.gz
	SRR9662123_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 8

Similar Datasets

Comprehensive analysis of the complexity and heterogeneity of the lncRNAs transcriptome in multiple myeloma

Project description:Comprehensive analysis of the complexity and heterogeneity of the lncRNAs transcriptome in multiple myeloma

| PRJNA634534 | ENA

Comprehensive analysis of the complexity and heterogeneity of the lncRNAs transcriptome in multiple myeloma

Project description:ssRNA-seq analysis of the transcriptional landscape of 38 multiple myeloma patients

2020-08-05 | GSE151063 | GEO

Comprehensive analysis of the complexity and heterogeneity of the lncRNAs transcriptome in multiple myeloma

Project description:RNA-seq analysis comparing the transcriptional landscape of LINC-SMILO silenced cells versus control cells in KMS-11 multiple myeloma cell line.

2021-05-12 | GSE134057 | GEO

The comprehensive analysis of total expression profiles in initial diagnosed multiple myeloma by genetic microarray

Project description:Long non-coding RNA (lncRNA) plays a vital role in Multiple Myeloma. Nevertheless, the exact expression features and functions of lncRNAs are still obscure.To investigate aberrantly expressed lncRNAs and mRNAs in MM, we screened the crucial differentially expressed lncRNA and mRNA in mononuclear cells from bone marrow of multiple myeloma patients and normal donors.These differentially expressed lncrnas are likely to play a key role in the development of MM, and may be used as a novel biomarker for the diagnosis or therapy of MM. We used microarrays to screen the candidate differentially expressed lncRNAs and mRNAs in mononuclear cells from bone marrow of multiple myeloma patients and normal donors .Subsequently,the candidate differentially expressed lncRNAs and mRNAs were verified by qRT-PCR.

2020-12-02 | GSE141260 | GEO

An unbiased lncRNAs dropout CRISPR-Cas9 screen reveals RP11-350G8.5 as a potential therapeutic target for Multiple Myeloma

Project description:Multiple Myeloma (MM) is an incurable malignancy characterised by alterations of coding and non-coding genes that promote tumour growth and drug resistance. Despite the crucial role of long non-coding-RNAs (lncRNAs) in myeloma genesis is established, the functional role of the non-coding RNAome in MM remains largely unknown. We performed an unbiased CRISPR-Cas9 recessive screen targeting 671 lncRNAs in MM cell lines unvealing and prioritising a list of novel onco-lncRNAs essential for MM cell fitness and associated with high expression and poor prognosis in MM patients. Among them, RP11-350G8.5 emerged as the most promising vulnerability for MM cells, irrespective of their resistance to the standard-of-care bortezomib. We i) validated the oncogenic role of RP11-350G8.5 in vitro and in vivo; ii) characterised its function in relation to the unfolded protein stress response and induction of immunogenic cell death, and iii) shed light on its sub-cellular localisation, structural and chemical predictions of RNA-G-quadruplex-forming regions to pave the way to the development of novel therapeutics.

2024-08-20 | GSE273796 | GEO

Expression data of newly diagnosed multiple myeloma and extramedullary myeloma

Project description:Despite the development of novel therapeutic agents, multiple myeloma (MM) remains incurable, owing mainly to inevitable relapse in almost all patients. Some relapses occur as extramedullary disease (EMD), which is rare but is the most aggressive event in MM patients. Extramedullary myeloma (EMM) has extraordinary heterogeneous biological and clinical features. Previous studies have shown that expression levels of LncRNAs and mRNAs in different stages of MM are different. This study analyzes the expression levels of LncRNAs and mRNAs in primary plasma cells (PCs) from MM and EMM patients.

2023-03-01 | GSE147841 | GEO

Single cell dissection of plasma cell heterogeneity in symptomatic and asymptomatic myeloma

Project description:Multiple myeloma (MM), a plasma cell (PC) malignancy, is the second most common blood cancer. Despite extensive research, disease heterogeneity within and between patients is poorly characterized, hampering efforts for early diagnosis and improved treatments. Here, we apply single cell RNA-seq to study the heterogeneity of 40 individuals along the MM progression spectrum. We define malignant PC at single cell resolution, demonstrating high inter-patient variability that can be explained by expression of known MM drivers and additional putative factors. Within newly diagnosed patients, we identify extensive sub-clonal structures for 10/29 patients. In asymptomatic patients with early disease and in minimal residual disease post-treatment, we detect tumor PC for a subset of the patients, with the same drivers of active myeloma. Single cell analysis of rare circulating tumor cells (CTC) allows detection of malignant PC, which reflect the BM disease. Our work establishes scRNA-seq for dissecting blood malignancies and devising detailed molecular characterization of tumor cells in symptomatic and asymptomatic patients.

2018-12-07 | GSE117156 | GEO

Computational prediction and experimental validation identify functionally conserved lncRNAs from zebrafish to human

Project description:Functional studies of long noncoding RNAs (lncRNAs) have long been hindered by a lack of methods to assess their evolution. Here, we present lncHOME (lncRNA Homology Explorer), a computational pipeline that identifies a unique coPARSE-lncRNA class with conserved genomic locations and patterns of RNA binding protein (RBP) binding sites. Remarkably, several hundred human coPARSE-lncRNAs can be evolutionarily traced to zebrafish. Using CRISPR-Cas12a knockout and rescue assays, we found that knocking out many human coPARSE-lncRNAs led to cell proliferation defects that were rescued by predicted zebrafish homologs. Knocking down the coPARSE-lncRNAs in zebrafish embryos caused severe developmental delays that were rescued by human homologs. Moreover, we verified that human, mouse, and zebrafish coPARSE-lncRNA homologs tend to bind similar RBPs with their conserved fuctions relying on specific RBP binding sites. Overall, our study demonstrates a comprehensive approach for studying functional conservation of lncRNAs and implicates numerous lncRNAs in regulating cellular physiology.

2024-01-26 | PXD046452 | Pride

Transcriptional heterogeneity overcomes super-enhancer disrupting drug combinations in multiple myeloma

Project description:Transcriptional heterogeneity overcomes super-enhancer disrupting drug combinations in multiple myeloma

| PRJNA1020864 | ENA

RIP-seq of lncRNAs interacting with EZH2 in INA-6 multiple myeloma cells

Project description:RIP-seq of lncRNAs interacting with EZH2 in INA-6 multiple myeloma cells

| PRJEB64003 | ENA